TickerFacts.

Adaptive Biotechnologies Corp (ADPT): Revenue

Annual figures by period end, from SEC filings.

$276.98M
Year ended 2025-12-31
$308.08M
Trailing 12 months to 2026-06-30
+14.3%
3-year compound annual growth
+23.0%
5-year compound annual growth
2017-12-31: $38.45M2018-12-31: $55.66M2019-12-31: $85.07M2020-12-31: $98.38M2021-12-31: $154.34M2022-12-31: $185.31M2023-12-31: $170.28M2024-12-31: $178.96M2025-12-31: $276.98M$276.98M
2017-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$276.98M+54.8%2026-02-26, From 2025-01-01
2024-12-31$178.96M+5.1%2026-02-26, From 2024-01-01
2023-12-31$170.28M-8.1%2026-02-26, From 2023-01-01
2022-12-31$185.31M+20.1%2025-03-03, From 2022-01-01
2021-12-31$154.34M+56.9%2024-02-29, From 2021-01-01
2020-12-31$98.38M+15.6%2023-02-14, From 2020-01-01
2019-12-31$85.07M+52.8%2022-02-15, From 2019-01-01
2018-12-31$55.66M+44.8%2021-02-24, From 2018-01-01
2017-12-31$38.45Mn/a2020-02-26, From 2017-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Adaptive Biotechnologies Corp (ADPT)2025-12-31$276.98M+54.8%
Vericel Corp (VCEL)2025-12-31$276.26M+16.5%
Iovance Biotherapeutics, Inc. (IOVA)2025-12-31$263.50M+60.6%
Vaxart, Inc. (VXRT)2025-12-31$237.26M+726.7%
Twist Bioscience Corp (TWST)2025-09-30$376.57M+20.3%
Krystal Biotech, Inc. (KRYS)2025-12-31$389.13M+33.9%
Immunocore Holdings plc (IMCR)2025-12-31$400.02M+29.0%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$178.03M+195.3%
REGENXBIO Inc. (RGNX)2025-12-31$170.44M+104.5%

Compare ADPT, VCEL, IOVA, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗